P4-3 is a PROTAC designed to induce degradation of CD26, a transmembrane glycoprotein with dual oncogenic functions overexpressed in NSCLC. Here, we employed label-free quantitative proteomics to characterize its global proteomic impact on H460 cells. Bottom-up proteomics was performed on samples treated with DMSO or P4-3 (24 hours, 6 biological replicates per group) to assess proteome-wide alterations. ​